Health
Researchers identify aluminum hydroxide/TLR9 agonist as potential adjuvant to improve RBD-based COVID-19 vaccine efficacy – News-Medical.net
The study findings reveal that RBD-based vaccines adjuvanted with the formulation can induce strong anti-SARS-CoV-2 neutralizing immunity in young and aged mice….
A team of scientists from the United States has recently developed a formulation of toll-like receptor 9 (TLR9) agonist and aluminum hydroxide to increase the immunogenicity of spike receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
The study findings reveal that RBD-based vaccines adjuvanted with the formulation can induce strong anti-SARS-CoV-2 neutralizing immunity in young and aged mice. The study is currently available on the bioRxiv* preprint server.
…
-
Noosa News18 hours agoHelicopter pilots saving lives, providing food and fodder in flooded outback Queensland
-
Noosa News22 hours ago’Lethal new opioids’ prompt Wide Bay pill testing call
-
General18 hours agoInternal Revenue Service starts cutting 20,000 workers
-
Noosa News17 hours agoMan killed, woman seriously injured in collision in Wongabel, Atherton Tablelands, Queensland